Benefit-risk balance of hormone replacement therapy: Cancers and mortality. Postmenopausal women management- CNGOF and GEMVi clinical practice guidelines

被引：2
|
作者：
Poudou, C. [1 ]
Baffet, H. [2 ,3 ]
Nadeau, C. [1 ]
Rolland, A-L [2 ,3 ]
Catteau-Jonard, S. [2 ,4 ]
Robin, G. [2 ,4 ]
机构：
[1] CHU Poitiers, Serv Gynecol Obstet & Med Reprod, 2 Rue Miletrie, F-86021 Poitiers, France
[2] CHU Lille, Serv Gynecol Med Orthogenie & Sexol, Hop Jeanne de Flandre, Ave Eugene Avinee, F-59073 Lille, France
[3] CHU Lille, Serv Assistance Med Procreat & Preservat Fertilit, Ave Eugene Avinee, F-59037 Lille, France
[4] Univ Lille, Fac Med, 2 Ave Eugene Avinee, F-59120 Loos, France
来源：
GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE | 2021年 / 49卷 / 05期
关键词：
Hormone replacement therapy (HRT); Breast cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Mortality; ESTROGEN PLUS PROGESTIN; ENDOMETRIAL CANCER; OVARIAN-CANCER; REPRODUCTIVE FACTORS; ESOPHAGEAL CANCER; COLORECTAL-CANCER; BREAST-CANCER; HEALTH; COHORT; INTERVENTION;
D O I：
10.1016/j.gofs.2021.03.031
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
The use of hormone replacement therapy (HRT) for menopausal women has been the subject of much controversy in recent years, particularly concerning the carcinologic risks. The purpose of this review is to evaluate the impact of the use of HRT on the risk of gynecological but also extra-gynecological cancers. The effect of the type and the duration of use of HRT in menopausal women will also be discussed. The beneficial impact of HRT on overall mortality is also an element that will be discussed and must be taken into account when evaluating the benefit-risk balance of HRT for menopausal women. (c) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：462 / 473
页数：12
相关论文
共 27 条
  • [1] Menopausal hormone therapy an cardiovascular risk. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Plu-Bureau, G.
    Mounier-Vehier, C.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 438 - 447
  • [2] Menopause hormone therapy and cognition. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Andre, G.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 448 - 454
  • [3] Menopause, menopause hormone therapy and osteoporosis. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Pouilles, J-M
    Gosset, A.
    Tremollieres, F.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 420 - 437
  • [4] Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines (Short version)
    Tremollieres, F.
    Chabbert-Buffet, N.
    Plu-Bureau, G.
    Rousset-Jablonski, C.
    Lecerf, J-M
    Duclos, M.
    Pouilles, J-M
    Gosset, A.
    Boutet, G.
    Hocke, C.
    Maris, E.
    Hugon-Rodin, J.
    Maitrot-Mantelet, L.
    Robin, G.
    Andre, G.
    Hamdaoui, N.
    Mathelin, C.
    Lopes, P.
    Graesslin, O.
    Fritel, X.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 305 - 317
  • [5] Menopause hormone treatment. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Gosset, A.
    Robin, G.
    Letombe, B.
    Pouilles, J-M
    Tremollieres, F.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 358 - 372
  • [6] Menopause and risk of thromboembolic events. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Hugon-Rodin, J.
    Perol, S.
    Plu-Bureau, G.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 455 - 461
  • [7] How to diagnose menopause? Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Rousset-Jablonski, C.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 318 - 328
  • [8] Nutritional advices for postmenopausal woman. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Lecerf, J-M
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 349 - 357
  • [9] Management of side effects under hormonal replacement therapy in menopausal women: Abnormal uterine bleeding. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines
    Hamdaoui, N.
    Boubli, L.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 474 - 484
  • [10] Differential diagnosis of vasomotor symptoms. Postmenopausal women management : CNGOF and GEMVi clinical practice guidelines
    Maitrot-Mantelet, L.
    Perol, S.
    Plu-Bureau, G.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2021, 49 (05): : 329 - 334
123